Foley Hoag has a long history of extensive involvement with the development of legislation and regulations affecting the biotechnology, pharmaceutical, medical device and healthcare provider industries. Our clients include a number of leading pharmaceutical, biotechnology and medical device companies regarding government strategies for legislative, regulatory and administrative matters. learn more

News more

  • Summer @ Foley Hoag LLPFoley Hoag Launches New Microsite for Law Students as 2009 On-campus Interviews Commence  [Read More]
  • Working Mother and Flex-Time Lawyers Recognize Foley Hoag  [Read More]
  • Foley Hoag Joins American Lawyer's Select Group of Top 50 A-List Firms  [Read More]
  • Live @ BIO 2008: Innovation, Commercialization, and Protecting Assets  [Read More]

Publications more

  • Hatch-Waxman Safe Harbor Inapplicable to Research Tools [Read More]
  • Massachusetts House and Senate Pass Compromise Restrictions on Pharmaceutical & Medical Device Marketing [Read More]
  • Medicare Datasheet [Read More]
  • Food and Drug Datasheet [Read More]
  • Massachusetts House Revises Legislation Concerning Proposed Pharmaceutical Gift Ban  [Read More]

Events more

October 16, 2008 Personalized Medicine Coalition [Read More] The Ohio State University Medical Center
Columbus, Ohio

Client Successes more

  • Orphan Drug Act
    Our lawyers represented clients under the Orphan Drug Act, which is credited with giving rise to the biotechnology industry, through its provision of seven years of marketing exclusivity to companies that develop drugs or biologics for patients with rare diseases. [Read More]
  • Reimbursement Strategies in the Fight Against Cancer
    We represented a leading biotechnology company in increasing hospital outpatient reimbursement for supportive anti-cancer therapy. [Read More]